Blood Test Guided Follow-up and Further Treatment After Lung Cancer Surgery
Tests blood-guided follow-up and treatment after surgery in non-small cell lung cancer.
Plain-language title generated from the registry record
Registry title: MRD-Guided Postoperative Surveillance and Adaptive Treatment for Resectable Lung Cancer
Key facts
- Where
- Beijing, ChinaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with stage IB-IIIA non-small cell lung cancer who had neoadjuvant immunotherapy with platinum chemotherapy and then radical surgery.
- Age
- 18 to under 85 years
- Sex
- All
- Disease stage
- Non-small cell lung cancer, pathologic stage IB-IIIA (8th TNM), after radical resection. No pure ground-glass nodule on imaging.
- Earlier treatment
- Must have completed standard neoadjuvant immunotherapy combined with platinum-based chemotherapy, then radical surgery.
- Biomarker or test result
- Tumor tissue and blood samples must be obtainable at all time-points set by the protocol.
Main reasons for not taking part
- Pathology after surgery shows something other than non-small cell lung cancer
- Any other cancer in the past 5 years
- Non-radical (R2) resection
- Pathologic stage IIIB-N3, IIIC, or IV
- Not enough or poor-quality blood or tissue samples
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 85 years old?
Source: NCT07894458, who can take part
Where in China
- Peking University People's HospitalBeijing, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Peking University People's Hospital
- Trial code
- NCT07894458
- Record updated
- 26 October 2026
- Original description
This study is a prospective single-arm clinical trial targeting patients with stage IB-IIIA non-small cell lung cancer (NSCLC) who have received neoadjuvant immunotherapy. The primary objective is to evaluate whether a personalized follow-up and adjuvant treatment strategy-based on the combination of ctDNA-based minimal residual disease (MRD) testing and pathological response-can effectively improve the 2-year postoperative recurrence-free survival (RFS). The study will enroll 100 patients scheduled for radical surgery who have undergone neoadjuvant immunotherapy (in combination with platinum-based chemotherapy). Patients will receive individualized follow-up and adjuvant therapy based on dynamic changes in ctDNA at various preoperative and postoperative timepoints, as well as pathological response. Adjuvant therapy will be recommended if patients do not achieve pathological complete response (pCR) after surgery, or if ctDNA testing is positive after neoadjuvant therapy or post-surgery. Only patients who achieve pCR and have negative ctDNA at both specified timepoints will forgo adjuvant therapy; these patients will undergo blood sampling at each routine follow-up, with adjuvant therapy initiated upon ctDNA seroconversion to positive. The primary endpoint is 2-year RFS after surgery; secondary endpoints include overall survival (OS) and the diagnostic rate of recurrence/metastasis based on ctDNA-MRD testing. This project aims to explore the refinement of adaptive treatment strategies in the neoadjuvant immunotherapy lung cancer population, with the ultimate goal of improving overall therapeutic efficacy and establishing a standardized, integrated postoperative management system suitable for lung cancer patients.Read full original descriptionShow less
Establishment of Post-Operative Optimal Surveillance Model and Adaptive Treatment Decision System Based on MRD Molecular Response Combined With Pathological Response Status
This study is a prospective single-arm clinical trial targeting patients with stage IB-IIIA non-small cell lung cancer (NSCLC) who have received neoadjuvant immunotherapy. The primary objective is to evaluate whether a personalized follow-up and adjuvant treatment strategy-based on the combination of ctDNA-based minimal residual disease (MRD) testing and pathological response-can effectively improve the 2-year postoperative recurrence-free survival (RFS). The study will enroll 100 patients scheduled for radical surgery who have undergone neoadjuvant immunotherapy (in combination with platinum-based chemotherapy). Patients will receive individualized follow-up and adjuvant therapy based on dynamic changes in ctDNA at various preoperative and postoperative timepoints, as well as pathological response. Adjuvant therapy will be recommended if patients do not achieve pathological complete response (pCR) after surgery, or if ctDNA testing is positive after neoadjuvant therapy or post-surgery. Only patients who achieve pCR and have negative ctDNA at both specified timepoints will forgo adjuvant therapy; these patients will undergo blood sampling at each routine follow-up, with adjuvant therapy initiated upon ctDNA seroconversion to positive. The primary endpoint is 2-year RFS after surgery; secondary endpoints include overall survival (OS) and the diagnostic rate of recurrence/metastasis based on ctDNA-MRD testing. This project aims to explore the refinement of adaptive treatment strategies in the neoadjuvant immunotherapy lung cancer population, with the ultimate goal of improving overall therapeutic efficacy and establishing a standardized, integrated postoperative management system suitable for lung cancer patients.
Inclusion: Signed written informed consent; Male or female, aged ≥ 18 and < 85 years; Radical resection performed, pathologic stage IB-IIIA (8th TNM) non-small-cell lung cancer; Tumor tissue and blood samples obtainable at all protocol-specified time-points; No pure ground-glass nodule on imaging; Completed standard neoadjuvant immunotherapy combined with platinum-based chemotherapy.
Exclusion: Contraindication to surgery preventing radical resection; Non-radical (R2) resection; History of any malignancy within the past 5 years; Any condition deemed unsuitable by the investigator (e.g., perioperative blood transfusion, severe psychiatric disorder precluding follow-up); Postoperative pathology shows other than NSCLC, including but not limited to benign lesions, small-cell carcinoma, metastasis, or indeterminate/inadequate histology; Insufficient or poor-quality blood or tissue samples; Pure ground-glass nodule on imaging; Pathologic stage IIIB-N3, IIIC, or IV on paraffin sections; Refusal or withdrawal of informed consent.